噻唑烷二酮类药物治疗糖尿病肾病的可能机制探讨_West China Medical Journal

Authors：

喻荷淋 ,  吴艳

Corresponding author：

吴艳, Email: cqfreshfish@163.com

Keywords：

噻唑烷二酮类药物; 糖尿病肾病; 机制

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】 噻唑烷二酮类（TZD）药物为有效的核转录因子过氧化酶增殖体活化受体γ的高选择性激动剂，具有非常广泛的作用，除了降低血糖、改善胰岛素抵抗外，还具有胰岛素增敏之外的作用如降低炎性因子的产生、减轻炎症反应和氧化应激、改善血流动力学、降低尿蛋白的排泄等。现仅就TZD对糖尿病肾病的直接肾保护作用及机制进行综述。

Citation： 喻荷淋,吴艳. 噻唑烷二酮类药物治疗糖尿病肾病的可能机制探讨. West China Medical Journal, 2011, 26(1): 125-128. doi: Copy

1.	Schnaper HW, Hayshids T, Hubchak SC, et al. TGF-beta signal transduction and meangial cell fibrogensis[J]. Am J Physiol Renal Physiol, 2003, 284(2): 243-252.
2.	Schrijvers BF, De Vriese AS. Novel insights in the treatment of diabetic nephropathy[J]. Acta Clin Belg, 2007, 62(5): 278-290.
3.	Zafiriou S, Stanners SR, Saad S, et al. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts[J]. J Am Soc Nephrol, 2005, 16(3): 638-645.
4.	Ha H, Yu MR, Choi YJ, et al. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells[J]. J Am Soc Nephrol, 2002, 13(4): 894-902.
5.	Ha SW, Kim HJ, Bae JS, et al. Elevation of urinary betaig-h3, transforming growth factor-beta induced protein in patients with type2 diabetes and nephropathy[J]. Diabetes Res Clin Pract, 2004, 65(2): 167-173.
6.	Makino H, Doi K, Hiuge A, et al. Impaired flow-mediated vascodilatation and insulin resistance in type 2 diabetic patients with albuminuria[J]. Diabetes Res Clin Pract, 2008, 79(1): 177-182.
7.	Florkowski CM. Mangement of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones[J]. Am J Cardiovasc Drugs, 2002, 2(1): 15-21.
8.	Ruiz-Ortega M, Lorenzo O, Egido J. Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear cells[J]. Kidney Int, 2000, 57(6): 2285-2298.
9.	Bao Y, Jia RH, Yuan J, et al. Rosiglitazone ameliorates diabetic nephriopathy by inhibiting reactive oxygen species and its downstream-signaling pathyways[J]. Pharmacology, 2007, 80(1): 57-64.
10.	Li Y, Wen X, Spataro BC, et al. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists[J]. J Am Soc Nephrol, 2006, 17(1): 54-65.
11.	Maeda A, Horikoshi S, Gohda T, et al. Pioglitazone attenuates TGF-beta(1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)-gamma[J]. Cell Biol Int, 2005, 29(6): 422-428.
12.	Dong FQ, Li H, Cai WM, et al. Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats[J]. Chin Med J, 2005, 117(7): 1040-1044.
13.	Zafiriou S, Stanners SR, Polhill TS, et al. Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses[J]. Kidney Int, 2004, 65(5): 1647-1653.
14.	Onozaki A, Midorikawa S, Sanada H, et al. Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidin edione[J]. Biochem Biophys Res Commun, 2004, 317(1): 24-29.
15.	Ghosh SS, Gehr TW, Ghosh S, et al. PPAR gamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase[J]. Kidney Int, 2003, 64(1): 52-62.
16.	Debril MB, Renaud JP, Fajas L, et al. The pleiotropic functions of peroxisome proliferators-activated receptor gamma[J]. J Mol Med, 2001, 79(1): 30-47.
17.	Inouel I, Goto SI, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells[J]. Metabolism, 2001, 50(1): 3-11.
18.	Alvarez-Maqueda M, El Bekay R, Alba G, et al. 15-deoxy-delta 12, 14-prostaglandin J2 induces heme oxygenase-1 gene expression in a reactive oxygen species-dependent manner in human lymphocytes[J]. J Biol Chem, 2004, 279(21): 21929-21937.
19.	Khan O, Riazi S, Hu X, et al. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone[J]. Am J Physiol Renal Physiol, 2005, 289(2): F442-F450.
20.	Negro R, Mangieri T, Dazzi D, et al. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients[J]. Diabetes Res Clin Pract. 2005, 70(1): 20-25.
21.	Wakino S, Hayashi K, Tatenatsu S, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats[J]. Hypertens Res, 2005, 28(3): 255-262.
22.	Ríos-Vázquez R, Marzoa-Rivas R, Gil-Ortega I, et al. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus[J]. Am J Cardiovasc Drugs, 2006, 6(4): 231-242.
23.	Meisner F, Walcher D, Gizard F, et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial[J]. Arterioscler Thromb Vasc Biol, 2006, 26(4): 845-850.
24.	Bakris GL, Ruilope LM, Mcmom SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria [J]. J Hypertens, 2006, 24(10): 2047-2055.
25.	Lee MY, Lee EY, Lee BJ, et al. Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats[J]. Yonsei Med J, 2007, 48(2): 301-307.
26.	Izzedine H, Launay-Vacher V, Buhaescu I, et al. PPAR-gamma-agonists’ renal effects[J]. Minerva Urol Nefrol, 2005, 57(4): 247-260.
27.	Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients[J]. Diabetes, 2005, 54(7): 2206-2211.
28.	Iglesias P, Díez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease[J]. Eur J Endorinol, 2006, 154(5): 613-621.

1. 　Schnaper HW, Hayshids T, Hubchak SC, et al. TGF-beta signal transduction and meangial cell fibrogensis[J]. Am J Physiol Renal Physiol, 2003, 284(2): 243-252.
2. 　Schrijvers BF, De Vriese AS. Novel insights in the treatment of diabetic nephropathy[J]. Acta Clin Belg, 2007, 62(5): 278-290.
3. 　Zafiriou S, Stanners SR, Saad S, et al. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts[J]. J Am Soc Nephrol, 2005, 16(3): 638-645.
4. 　Ha H, Yu MR, Choi YJ, et al. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells[J]. J Am Soc Nephrol, 2002, 13(4): 894-902.
5. 　Ha SW, Kim HJ, Bae JS, et al. Elevation of urinary betaig-h3, transforming growth factor-beta induced protein in patients with type2 diabetes and nephropathy[J]. Diabetes Res Clin Pract, 2004, 65(2): 167-173.
6. 　Makino H, Doi K, Hiuge A, et al. Impaired flow-mediated vascodilatation and insulin resistance in type 2 diabetic patients with albuminuria[J]. Diabetes Res Clin Pract, 2008, 79(1): 177-182.
7. 　Florkowski CM. Mangement of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones[J]. Am J Cardiovasc Drugs, 2002, 2(1): 15-21.
8. 　Ruiz-Ortega M, Lorenzo O, Egido J. Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear cells[J]. Kidney Int, 2000, 57(6): 2285-2298.
9. 　Bao Y, Jia RH, Yuan J, et al. Rosiglitazone ameliorates diabetic nephriopathy by inhibiting reactive oxygen species and its downstream-signaling pathyways[J]. Pharmacology, 2007, 80(1): 57-64.
10. 　Li Y, Wen X, Spataro BC, et al. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists[J]. J Am Soc Nephrol, 2006, 17(1): 54-65.
11. 　Maeda A, Horikoshi S, Gohda T, et al. Pioglitazone attenuates TGF-beta(1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)-gamma[J]. Cell Biol Int, 2005, 29(6): 422-428.
12. 　Dong FQ, Li H, Cai WM, et al. Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats[J]. Chin Med J, 2005, 117(7): 1040-1044.
13. 　Zafiriou S, Stanners SR, Polhill TS, et al. Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses[J]. Kidney Int, 2004, 65(5): 1647-1653.
14. 　Onozaki A, Midorikawa S, Sanada H, et al. Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidin edione[J]. Biochem Biophys Res Commun, 2004, 317(1): 24-29.
15. 　Ghosh SS, Gehr TW, Ghosh S, et al. PPAR gamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase[J]. Kidney Int, 2003, 64(1): 52-62.
16. 　Debril MB, Renaud JP, Fajas L, et al. The pleiotropic functions of peroxisome proliferators-activated receptor gamma[J]. J Mol Med, 2001, 79(1): 30-47.
17. 　Inouel I, Goto SI, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells[J]. Metabolism, 2001, 50(1): 3-11.
18. 　Alvarez-Maqueda M, El Bekay R, Alba G, et al. 15-deoxy-delta 12, 14-prostaglandin J2 induces heme oxygenase-1 gene expression in a reactive oxygen species-dependent manner in human lymphocytes[J]. J Biol Chem, 2004, 279(21): 21929-21937.
19. 　Khan O, Riazi S, Hu X, et al. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone[J]. Am J Physiol Renal Physiol, 2005, 289(2): F442-F450.
20. 　Negro R, Mangieri T, Dazzi D, et al. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients[J]. Diabetes Res Clin Pract. 2005, 70(1): 20-25.
21. 　Wakino S, Hayashi K, Tatenatsu S, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats[J]. Hypertens Res, 2005, 28(3): 255-262.
22. 　Ríos-Vázquez R, Marzoa-Rivas R, Gil-Ortega I, et al. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus[J]. Am J Cardiovasc Drugs, 2006, 6(4): 231-242.
23. 　Meisner F, Walcher D, Gizard F, et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial[J]. Arterioscler Thromb Vasc Biol, 2006, 26(4): 845-850.
24. 　Bakris GL, Ruilope LM, Mcmom SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria [J]. J Hypertens, 2006, 24(10): 2047-2055.
25. 　Lee MY, Lee EY, Lee BJ, et al. Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats[J]. Yonsei Med J, 2007, 48(2): 301-307.
26. 　Izzedine H, Launay-Vacher V, Buhaescu I, et al. PPAR-gamma-agonists’ renal effects[J]. Minerva Urol Nefrol, 2005, 57(4): 247-260.
27. 　Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients[J]. Diabetes, 2005, 54(7): 2206-2211.
28. 　Iglesias P, Díez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease[J]. Eur J Endorinol, 2006, 154(5): 613-621.

West China Medical Journal

噻唑烷二酮类药物治疗糖尿病肾病的可能机制探讨

Abstract Full text Figures/Tables Video References Cited by

Format

Content